Na Li

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Inflammatory Response

Patient Reported

Top Venues

Cancer research communications

Proceedings of the National Academy of Sciences of the United States of America

Wiley interdisciplinary reviews. RNA

This page only lists publications with an associated author ORCID identifier.

Publications

Na Li, Zhouting Zhu, Yufei Deng, Rachel Tang, Hui Hui, Yuqi Kang, Tariq M Rana
KIAA1429/VIRMA promotes breast cancer progression by m 6 A-dependent cytosolic HAS2 stabilization. EMBO reports (2023)
Zhouting Zhu, Rachel Tang, Sarah Huff, Indrasena Reddy Kummetha, Lingling Wang, Na Li, Tariq M Rana
Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. Cancer research communications 3 (1) (2023)
Zhouting Zhu, Rachel Tang, Sarah Huff, Indrasena Reddy Kummetha, Lingling Wang, Na Li, Tariq M Rana
Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. Cancer research communications 3 (1) (2023)
Na Li, Tariq M Rana
Regulation of antiviral innate immunity by chemical modification of viral RNA. Wiley interdisciplinary reviews. RNA 13 (6) (2022)
Na Li, Yuqi Kang, Lingling Wang, Sarah Huff, Rachel Tang, Hui Hui, Kriti Agrawal, Gwendolyn Michelle Gonzalez, Yinsheng Wang, Sandip Pravin Patel, Tariq M Rana
ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America 117 (33) (2020)